Edition:
United Kingdom

Biocartis And Bristol-Myers Squibb Sign Agreement For MSI Testing With Immuno-Oncology Therapies


Tuesday, 12 Mar 2019 

March 12 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND BRISTOL-MYERS SQUIBB SIGN COLLABORATION AGREEMENT FOR MSI TESTING WITH IMMUNO-ONCOLOGY THERAPIES. 

Company Quote

10.0
0.1 +1.01%
4:36pm BST